Fig. 2: Relative risk of death within 30 days after receiving convalescent plasma transfusion from near-sourced plasma vs. distantly sourced plasma. | Nature Communications

Fig. 2: Relative risk of death within 30 days after receiving convalescent plasma transfusion from near-sourced plasma vs. distantly sourced plasma.

From: Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors

Fig. 2

This forest plot shows the relative risk of death associated with receiving near-sourced convalescent plasma vs. distantly sourced (≤150 miles vs. >150 miles). The subgroups are the 12 mutually exclusive categories of donor region and patient disease severity. The pooled estimate captures the combined effect across subgroups. Patient disease severity (denoted by color) was defined as follows: Early treatment captures either days to transfusion ≤3 and/or symptom onset to infusion was <7 days, No complications captures no observed risk factors for severe COVID-19 (e.g., respiratory failure; see Supplemental Table 1), Some complications captures 1–2 severe risk factors, and With complications captures 3+ severe risk factors. The pooled estimate from all the subgroups is based on the Cochran–Mantel–Haenszel estimator. Relative risk point estimates are represented by circles and Ι bars indicate 95% confidence intervals.

Back to article page